Apparent Complete Response of a Treatment Refractory and Recurrent Squamous Cell Carcinoma Lesion to Photochemical Internalization: A Clinical Case Study

Photochem Photobiol. 2020 May;96(3):680-683. doi: 10.1111/php.13210. Epub 2020 Mar 17.

Abstract

Photochemical internalization (PCI) depends on the delivery of sublethal photodynamic reaction to facilitate the work of a chemotherapeutic agent. We discuss our experience in managing a patient with extensive squamous cell carcinoma of the right face and scalp under the TPCS2a -based bleomycin PCI treatment protocol. In this case, an 84-year-old Caucasian received 0.25 mg kg-1 of TPCS2a (Amphinex® , PCI Biotech AS, Oslo, Norway). Surface illumination photochemical internalization was carried out after 4 days, which was preceded by the chemotherapeutic agent infusion (Bleomycin). After one week from the illumination time, tissue necrosis was evident and tumor shrinkage was most noticeable at day 14 postillumination. Follow-up at 6 weeks continued to show tissue healing and regeneration with no clinical evidence of recurrence. Multiple surgical biopsies were taken at 1 and 3 months postillumination and found to be tumor free. PCI's depth of effect has been very significant with negligible damage to the collateral tissues. This technology has a role in interventional oncology especially when managing challenging cases.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic / therapeutic use
  • Bleomycin / therapeutic use
  • Face
  • Humans
  • Male
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use*
  • Remission Induction
  • Scalp
  • Skin Neoplasms / drug therapy*
  • Squamous Cell Carcinoma of Head and Neck / drug therapy*
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Photosensitizing Agents
  • Bleomycin